The Fintech Revolution Continues! Pine Labs IPO Opens on Nov 07- Check GMP, Price Band, Lot size, Dates & Key Details
Pine Labs IPO opens for subscription: Fintech major Pine Labs has unveiled its ₹3,900 crore IPO, pricing shares in the range of ₹210–₹221 apiece with a face value of ₹1. The Pine Labs IPO features a blend of new equity issuance and an offer for sale by existing stakeholders, highlighting strong investor participation expectations.
What is the Pine Labs IPO and how is it structured?
Offer Structure at a Glance
| Item | Details |
|---|---|
| Price band | ₹210 – ₹221 per share (face value ₹1) |
| Fresh issue size | Up to ₹2,080 crore (≈ ₹2,080 crore) |
| Offer-For-Sale (OFS) by existing investors | ~82.48 lakh shares |
| Investor quota | QIB: ≥75%, NII: ≤15%, Retail: ≤10% |
| Employee reservation | ₹25 crore reserved; employees receive ₹21 per share discount on final price |
| Lead managers | Axis Capital, Morgan Stanley, Citi, J.P. Morgan, Jefferies India |
| Registrar | KFin Technologies Ltd |
** Pine Labs IPO DRHP: Click Here
What are the Pine IPO Labs Key Dates?
| Event | Date |
|---|---|
| Anchor book opens | 6 Nov 2025 |
| IPO opens for subscription | 7 Nov 2025 |
| IPO closes for subscription | 11 Nov 2025 |
| Allotment basis finalised | 12 Nov 2025 |
| Refunds credited & Demat credits | 13 Nov 2025 |
| Expected listing date (BSE & NSE) | 14 Nov 2025 |
Why this matters?
The structure, fresh + OFS – means Pine Labs raises fresh capital and gives early investors an exit route. The 10% retail quota means retail investors contend for limited shares. The high valuation implies big growth expectations baked into the price band.
Why Has The Pine Labs IPO Price Band Been Set at ₹210-₹221?
Valuation perspective
– At ₹210 per share, implied P/E ~144.83×; at ₹221 ~152.41×.
– Industry peers trade around ~61.78× P/E.
High multiple suggests investor confidence in Pine Labs’ growth; yet it also indicates risk if growth slows.
What is Pine Labs IPO Grey market premium (GMP)?
Market reports show the Pine Labs IPO GMP (grey-market premium) reportedly reached ₹60 ahead of the opening (around 27.14%). Early investors have seen large gains. This hints at strong demand but also possible listing-day correction if expectations aren’t met.
What this means for investors?
For retail investors:
- The high valuation means you’re buying future growth, not current profits.
- As losses have been reported historically, apply only if comfortable with 2-3 year horizon.
- Quota is small (10%); allotment may be highly competitive.
- Even though price band offers some discount vs unlisted valuations, margin of safety is moderate.
What does Pine Labs do – business, performance & recent update?
Company profile & business model
Founded in 1998, Pine Labs is a merchant-commerce fintech platform offering POS devices, payment processing, BNPL (Buy Now Pay Later) solutions, merchant financing, loyalty & gift-card solutions, e-commerce and online-payment infrastructure. It serves small to large merchants in India and abroad (South-East Asia, UAE) and counts major customers like Amazon Pay, LG Electronics, Flipkart, and Redington; major banks include HDFC Bank, Axis Bank, ICICI Bank.
Recent Financial Snapshot
| Period ended | Revenue (₹ crore) | PAT/Loss (₹ crore) |
|---|---|---|
| FY2023 | 1,690.44 | –265.15 |
| FY2024 | 1,824.16 | –341.90 |
| FY2025 | 2,327.09 | –145.49 |
Recent quarter data (June 2025) shows revenue of ~₹653.08 crore and PAT of ~₹4.79 crore (indicating a turnaround).
These numbers indicate revenue growth, a narrowing of loss, and signs of operational improvement — key for a high-valuation IPO.
Use of Pine Labs IPO Proceeds
The fresh issue part will be used for:
- Repayment or pre-payment of borrowings of the company and its subsidiaries.
- Investment in overseas subsidiaries (e.g., Qwikcilver Singapore, Pine Payment Solutions Malaysia, Pine Labs UAE) to expand outside India.
- Investment in IT assets, cloud infrastructure, technology development and procurement of digital checkout points (DCPs).
- General corporate purposes and potential inorganic acquisitions.
Conclusion & Takeaway
The Pine Labs IPO price band of ₹210-₹221 offers an opportunity to participate in a major fintech listing. For Indian investors, this means access to one of the fastest-growing digital-payments platforms at the cusp of profitability and international expansion.
Takeaway: If you believe the digital-payments wave will continue unabated, Pine Labs may merit inclusion—especially for a medium to long-term view. However, if you’re seeking short-term listing gains or are risk-averse given high P/E, you may prefer to wait and watch.
Pine Labs IPO FAQs: Subscription, Allotment, Listing & Retail Quota
What is the Pine Labs IPO issue size & structure?
The IPO comprises a fresh issue of up to ~₹2,080 crore and an Offer-for-Sale (OFS) of ~82.48 lakh shares by existing investors.
When can I subscribe to the Pine Labs IPO?
Subscription opens on 7 Nov 2025 and closes on 11 Nov 2025.
What is the Pine Labs IPO price band?
Price band is ₹210 to ₹221 per share (face value ₹1).
What is the expected listing date of Pine Labs IPO?
The provisional listing date is 14 Nov 2025 on both the BSE and NSE.
What proportion is reserved for retail investors?
Up to 10% is reserved for retail individual investors, while QIBs get ≥75% and NIIs up to 15%.
How to apply and check allotment status of Pine Labs IPO?
Apply via ASBA through your bank’s net-banking or using UPI via your broker. Post the allotment date (12 Nov), check status on the registrar’s portal (KFin Technologies) or the NSE website.
What should retail investors consider before applying?
Key considerations: high valuation, limited retail quota, recent profitability turnaround, sector competition (fintech/payments). Apply only if you are comfortable with a multi-year view, not just listing-day gains.
Click Here to know more market & IPO related news and updates.
Disclaimer: The views and investment insights provided here are based on publicly available information and do not constitute financial advice. Readers are advised to conduct their own research or consult certified financial experts before making investment decisions.
